English-language podcasts

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

SELLAS' AML Survival Win Sets Up Its FDA Push & Isomorphic Raises $5B

13 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

SELLAS reports median survival of 24.0 months with its vaccine versus 14.7 with investigator-chosen care in REGAL, a Phase 3 trial in later-remission AML; we unpack the filing stakes and topline limits. Isomorphic Labs raises $5 billion to move AI drug discovery toward human trials. We examine GSK's Nuvalent-derived Nelkarmi (neladalkib) approval for previously treated ALK-positive lung cancer and new details in the existing FDA rejection letter for Summit's ivonescimab. The roundup covers Beren's Lembaz (adrabetadex) in infantile-onset Niemann-Pick type C, Novartis' Cosentyx (secukinumab) in polymyalgia rheumatica, and Helus' investigational HLP003 depression results—with evidence limits and safety tradeoffs. Alex Mercer and Maya Patel host.

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Daily Roundup | Celldex Ends Eczema Program & Revolution Medicines Updates Pancreatic Cancer Data (Delayed Nov. 19)

7 min

Delayed edition for Thursday, November 19, 2026. Celldex says it is ending barzolvolimab development in atopic dermatitis after its Phase 2 trial missed the primary itch endpoint. Revolution Medicines reports single-arm data for Rasonque (daraxonrasib) plus chemotherapy in first-line metastatic pancreatic cancer; a separate randomized study is designed to show what the drug adds. The roundup covers Pyxis Oncology’s Phase 1 micvotabart pelidotin data in head and neck cancer, the AbbVie–DISCO oncology discovery deal and Recursion’s proposed REC-4881 trial in familial adenomatous polyposis. Johnson & Johnson files to expand Caplyta (lumateperone) to manic or mixed episodes in bipolar I disorder, Novartis raises three peak sales forecasts, and a US biotech commission assesses China’s pharma competitiveness. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com (https://thepharmacloseout.com/).

Discuss this episode

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Daily Roundup | Pfizer’s $330M Upfront CAR-T Bet & Infilbray Approved for Type 3 Gaucher Neurologic Symptoms

12 min

Pfizer commits $330 million upfront to license three autoimmune CAR-T programs from Starna Therapeutics before human trials — the lead in this delayed November 18 edition. Sanofi’s Infilbray (venglustat) is the first FDA-approved treatment for neurological symptoms of type 3 Gaucher disease, with clearer trial evidence for cognition than for movement alone. Regeneron reports FDA approval of Livsayis (cemdisiran), dosed every 12 weeks for AChR-positive adults with generalized myasthenia gravis. The roundup covers Biogen’s diranersen follow-up in early Alzheimer’s disease, Merck’s halt to Phase 3 nemtabrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma, and the FDA’s plan to expand review sharing for overseas filings. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com (https://thepharmacloseout.com/).

Discuss this episode

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Daily Roundup | J&J to Buy Ollin for $2.2B Upfront & Roche’s Wilserdly Combo Approved for Breast Cancer

12 min

In this delayed Monday closeout, Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, and Blackstone agreed to fund Phase 3 work on OLN324 in wet AMD and diabetic macular edema if the acquisition closes. The FDA approved Roche's Wilserdly (giredestrant) with everolimus for ESR1-mutated advanced breast cancer after endocrine therapy. In the daily roundup: CG Oncology's cretostimogene bladder cancer data, Servier's Ojemda (tovorafenib) follow-up in pediatric low-grade glioma, Lilly's Calytrix Bio deal, AstraZeneca's Klygefa (gefurulimab) approval in myasthenia gravis, Novo Nordisk's semaglutide data in children, and AriBio's split AR1001 Alzheimer's result. Alex Mercer and Maya Patel host.

Discuss this episode

Community Poll

Employees should usually have a say in whether their work requires office attendance.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

You are vegetarian, but the leftover steak is headed for the trash. Do you eat it?

A vegetarian avoids buying meat because of animal welfare concerns. At work events, untouched meat is routinely thrown away, and eating it would neither increase demand nor cause another animal to be harmed.

Should a moral practice be judged by its consequences or its consistency?

Explore this quandary